Conclusion

Oncologist

Volumn 13, Issue SUPPL. 1, 2008, Pages 37-46

  Bunn, Paul A ^a   Thatcher, Nick ^b  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^b CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

Angiogenesis inhibitors protein kinase inhibitors; Antimetabolites; Antineoplastic agents; Non small cell lung carcinoma

Indexed keywords

BEVACIZUMAB; BGC 945; CARBOPLATIN; CETUXIMAB; CISPLATIN; DIHYDROFOLATE REDUCTASE INHIBITOR; DOCETAXEL; ENZASTAURIN; ERLOTINIB; GEFITINIB; GEMCITABINE; NAVELBINE; OXALIPLATIN; PACLITAXEL; PEMETREXED; SORAFENIB; THYMIDYLATE SYNTHASE INHIBITOR; UNCLASSIFIED DRUG; VINFLUNINE; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR;

ACNE; ADD ON THERAPY; ALOPECIA; ARTHRALGIA; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DIVERTICULITIS; DOSAGE SCHEDULE COMPARISON; DRUG ANTAGONISM; DRUG EFFICACY; DRUG POTENTIATION; DYSPNEA; FATIGUE; HUMAN; INFECTION; LOADING DRUG DOSE; LUNG NON SMALL CELL CANCER; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROPATHY; NEUTROPENIA; PRIORITY JOURNAL; PROTEINURIA; QUALITY OF LIFE; RASH; REVIEW; THROMBOCYTOPENIA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VOMITING; CANCER STAGING; LUNG TUMOR; PATHOLOGY; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; PROTEIN KINASE INHIBITORS; TREATMENT OUTCOME;

EID: 42049101034     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.13-S1-37     Document Type: Review

References (77)

1. Taguchi F, Solomon B, Gregorc V et al. Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptortyrosine kinase inhibitors: A multi-cohort cross-institutional study. J Natl Cancer Inst 2007;99:838-846.
2. Bunn PA Jr. Chemotherapy for advanced non-small-cell lung cancer: Who, what, when, why? J Clin Oncol 2002;20(18 suppl):23S-33S.
3. Natale RB. Gemcitabine-containing regimens vs others in first-line treatment of NSCLC. Oncology (Williston Park) 2004;18(suppl 5):27-31.
4. Le Chevalier T, Scagliotti G, Natale R et al. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: A meta-analysis of survival outcomes. Lung Cancer 2005;47:69-80.
5. Jiang J, Liang X, Zhou X et al. A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer. Lung Cancer 2007;57:348-358.
6. Rinaldi M, Cauchi C, Gridelli C. First line chemotherapy in advanced or metastatic NSCLC. Ann Oncol 2006;17(suppl 5):v64-v67.
7. Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-98.
8. Zatloukal P, Petruzelka L, Zemanova M et al. Gemcitabine plus cisplatin vs. gemcitabine pluscarboplatin in stage IIIb and IV non-small cell lung cancer: A phase III randomized trial. Lung Cancer 2003;41:321-331.
9. Rosell R, Gatzemeier U, Betticher DC et al. Phase III randomized trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: A cooperative multinational trial. Ann Oncol 2002;13:1539-1549.
10. Fossella F, Pereira JR, von Pawel J et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorel-bine plus cisplatin for advanced non-small-cell lung cancer: The TAX326 study group. J Clin Oncol 2003;21:3016-3024.
11. Ardizzoni A, Boni L, Tiseo M et al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: An individual patient data meta-analysis. J Natl Cancer Inst 2007;99:847-857.
12. Shepherd FA, Dancey J, Arnold A et al. Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced non-small cell lung carcinoma: A study of the National Cancer Institute of Canada Clinical Trials Group. Cancer 2001;92:595-600.
13. Manegold C, Gatzemeier U, von Pawel J et al. Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA) and cisplatin: A multicenter phase II trial. Ann Oncol 2000;11:435-440.
14. Scagliotti G. Purvish P, von Pawel J et al. Phase III study of pemetrexed plus cisplatin versus gemcitabine plus cisplatin in chemonaive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). WCLC 2007 Presidential Symposium. J Thorac Oncol 2007;2(suppl 4):S306.
15. Zinner RG, Fossella FV, Gladish GW et al. Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced non-small cell lung cancer. Cancer 2005;104:2449-2456.
16. Masotti A, Zannini G, Gentile A et al. Activity of gemcitabine and carboplatin in advanced non-small cell lung cancer: A phase II trial. Lung Cancer 2002;36:99-103.
17. Belani CP, Einzig A, Bonomi P et al. Multicenter phase II trial of docetaxel and carboplatin in patients with stage IIIB and IV non-small-cell lung cancer. Ann Oncol 2000;11:673-678.
18. Langer CJ, Leighton JC, Comis RL et al. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: A phase II toxicity, response, and survival analysis. J Clin Oncol 1995;13:1860-1870.
19. Crino L, Scagliotti G, Marangolo M et al. Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: A phase II study. J Clin Oncol 1997;15:297-303.
20. Scagliotti GV, Kortsik C, Dark GG et al. Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: A multicenter, randomized, phase II trial. Clin Cancer Res 2005;11:690-696.
21. Kelly K, Crowley J, Bunn PA Jr et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: A Southwest Oncology Group trial. J Clin Oncol 2001;19:3210-3218.
22. Scagliotti GV, De Marinis F, Rinaldi M et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002;20:4285-4291.
23. Herbst RS, Prager D, Hermann R et al. TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005;23:5892-5899.
24. Miller VA, Herbst R, Prager D et al. Long survival of never smoking non-small cell lung cancer (NSCLC) patients treated with erlotinib HC1 (OSI-774) and chemotherapy: Sub-group analysis of TRIBUTE. J Clin Oncol 2004;22(14 suppl):7061.
25. Gatzemeier U, Pluzanska A, Szczesna A et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: The Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007;25:1545-1552.
26. Giaccone G, Herbst RS, Manegold C et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 1. J Clin Oncol 2004;22:777-784.
27. Herbst RS, Giaccone G, Schiller JH et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial-INTACT 2. J Clin Oncol 2004;22:785-794.
28. Davies AM, Ho C, Lara PN Jr et al. Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer. Clin Lung Cancer 2006;7:385-388.
29. Li T, Ling YH, Goldman ID et al. Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells. Clin Cancer Res 2007;13:3413-3422.
30. Kabbinavar F, Ross H, Martins R et al. Erlotinib (E) as a single agent or intercalated with carboplatin and paclitaxel (ECP) in an EGFR bio-marker-selected, previously untreated NSCLC population: D2-03. J Thorac Oncol 2007;2(suppl 4):S394.
31. Italiano A. Targeting the epidermal growth factor receptor in colorectal cancer: Advances and controversies. Oncology 2006;70:161-167.
32. Rosell R, Daniel C, Ramlau R et al. Randomized phase II study of cetuximab in combination with cisplatin (C) and vinorelbine (V) vs. CV alone in first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR)-expressing advanced non-small-cell lung cancer (NSCLC). J Clin Oncol 2004;22(suppl 14):7012.
33. Belani CP, Ramalingam S, Schreeder M et al. Phase II study of cetuximab in combination with carboplatin and docetaxel for patients with advanced/metastatic non-small cell lung cancer (NSCLC). J Clin Oncol 2007;25(18 suppl):7643.
34. Butts CA, Bodkin D, Middleman EL et al. Gemcitabine/platinum alone or in combination with cetuximab as first-line treatment for advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2007;25(18 suppl):7539.
35. ImClone Systems Incorporated. Data Available From ERBITUX® Phase III Study in First-Line Treatment of Advanced Lung Cancer. Press Release, July 12, 2007. Available at http://phx.corporate-ir.net/phoe-nix.zhtml?c=97689&p= irol-newsArticle&ID=1025428&highlight. Accessed August 3, 2007.
36. Merck. Erbitux Phase III Study - FLEX Increases Overall Survival in First-Line Treatment of Non-Small Cell Lung Cancer. Press Release, September 11, 2007. Available at http://www.merck.de/servlet/PB/menu/1007020/index.html. Accessed August 3, 2007.
37. Cappuzzo F, Hirsch FR, Rossi E et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005;97:643-655.
38. Hirsch FR, Varella-Garcia M, McCoy J et al. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: A Southwest Oncology Group study. J Clin Oncol 2005;23:6838-6845.
39. Adjei AA, Molina JR, Hillman SL et al. A front-line window of opportunity phase II study of sorafenib in patients with advanced non-small cell lung cancer: A North Central Cancer Treatment Group study. J Clin Oncol 2007;25(18 suppl):7547.
40. Gridelli C, Rossi A, Mongillo F et al. A randomized phase II study of sorafenib/gemcitabine or sorafenib/erlotinib for advanced non-small-cell lung cancer in elderly patients or patients with a performance status of 2: Treatment rationale and protocol dynamics. Clin Lung Cancer 2007;8:396-398.
41. ClinicalTrials.gov. A randomized (phase II), double-blind, multicenter phase I/II trial of pemetrexed, carboplatin plus or minus sorafenib in the first-line treatment of patients with stage IIIb or IV non-small cell lung cancer. Available at http://clinicaltrials.gov/show/NCT00473486. Accessed August 3, 2007.
42. ClinicalTrials.gov. A randomized controlled trial comparing safety and efficacy of carboplatin and paclitaxel plus or minus sorafenib (BAY 43-9006) in chemonaive patients with stage IIIB-IV non-small cell lung cancer. Available at http://clinicaltrials.gov/show/NCT00300885. Accessed August 3, 2007.
43. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-2550.
44. Manegold C, von Pawel J, Zatloukal P et al. Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naïve patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC):BO17704. J Clin Oncol 2007;25(18 suppl):LBA7514.
45. William WN, Kies MS, Fossella FV et al. Phase II study of bevacizumab in combination with docetaxel and carboplatin in patients with meta-static non-small cell lung cancer (NSCLC). J Clin Oncol 2007;25(18 suppl):18098.
46. Dalsania CJ, Hageboutros A, Harris E et al. Phase II trial of bevacizumab plus pemetrexed and carboplatin in previously untreated advanced nonsquamous non-small cell lung cancer. J Clin Oncol 2007;25(18 suppl):18163.
47. Patel JD, Hensing TA, Villa for V et al. Pemetrexed and carboplatin plus bevacizumab for advanced non-squamous non-small cell lung cancer (NSCLC): Preliminary results. J Clin Oncol 2007;25(18 suppl):7601.
48. Bria E, Cuppone F, Ciccarese M et al. Weekly docetaxel as second line chemotherapy for advanced non-small-cell lung cancer: Meta-analysis of randomized trials. Cancer Treat Rev 2006;32:583-587.
49. Chen YM, Shih JF, Perng RP et al. A randomized trial of different docetaxel schedules in non-small cell lung cancer patients who failed previous platinum-based chemotherapy. Chest 2006;129:1031-1038.
50. Camps C, Massuti B, Jimenez A et al. Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: A Spanish Lung Cancer Group trial. Ann Oncol 2006;17:467-472.
51. Gridelli C, Gallo C, Di Maio M et al. A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study. Br J Cancer 2004;91:1996-2004.
52. Pérez-Soler R, Chachoua A, Hammond LA et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004;22:3238-3247.
53. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-132.
54. Astra Zeneca. Iressa web site. Availability. Available at http://www.iressa.com/iressaHCP/9898J2840_7_1_0.aspx. Accessed March 8, 2007.
55. U.S. Food and Drug Administration/Center for Drug Evaluation and Research. Gefitinib (Marketed as Iressa) Information. FDA Alert, 2005. Available at http://www.fda.gov/cder/drug/infopage/gefitinib/default.htm. Accessed February 22, 2007.
56. Thatcher N. Chang A, Parikh P et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005;366:1527-1537.
57. Nishikawa M, Kusano N, Yoshimoto N et al. [Prolonged survival of gefitinib treatment in patients with advanced and previously treated non-small cell lung cancer.] Gan To Kagaku Ryoho 2006;33:1437-1440. In Japanese.
58. Ho C. Murray N, Laskin J et al. Asian ethnicity and adenocarcinoma histology continues to predict response to gefitinib in patients treated for advanced non-small cell carcinoma of the lung in North America. Lung Cancer 2005;49:225-231.
59. Hirsch FR, Varella-Garcia M. Bunn PA Jr et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 2006;24:5034-5042.
60. Hanna N, Shepherd FA, Fossella FV et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-1597.
61. Heist RS, Fidias P, Huberman M et al. Phase II trial of oxaliplatin, pemetrexed, and bevacizumab in previously-treated advanced non-small cell lung cancer(NSCLC). J Clin Oncol 2007;25(18 suppl):7700.
62. Fehrenbacher L, O'Neill V, Belani CP et al. A phase II, multicenter, randomized clinical trial to evaluate the efficacy and safety of bevacizumab in combination with either chemotherapy (docetaxel or pemetrexed) or erlotinib hydrochloride compared with chemotherapy alone for treatment of recurrent or refractory non-small cell lung cancer. J Clin Oncol 2006;24(18 suppl):7062.
63. Herbst RS, Johnson DH, Mininberg E et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005; 23:2544-2555.
64. ClinicalTrials.gov. Atlas AVF 3671 (Genentech). A randomized, double-blind, placebo-controlled, phase IIIb trial comparing bevacizumab therapy with or without erlotinib after completion of chemotherapy with bevacizumab for the first-line treatment of locally advanced or metastatic non-squamous non-small cell lung cancer. Available at http://clinicaltrials.gov/show/ NCT00257608. Accessed August 3, 2007.
65. ClinicalTrials.gov. A phase III, multicenter, placebo-controlled, double-blind, randomized clinical trial to evaluate the efficacy of bevacizumab in combination with Tarceva (erlotinib) compared with Tarceva alone for treatment of advanced non-small cell lung cancer (NSCLC) after failure of standard first-line chemotherapy. Available at http://clinicaltrials.gov/show/ NCT00l30728. Accessed August 3, 2007.
66. Kim ES, Mauer AM, Tran HT et al. A phase II study of cetuximab, an epidermal growth factor receptor (EGFR) blocking antibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced non-small cell lung cancer: Final report. Proc Am Soc Clin Oncol 2003;22:642.
67. Jalal SI, Waterhouse D. Edelman M et al. Pemetrexed plus cetuximab in patients with recurrent non-small cell lung cancer (NSCLC): A phase IIIa dose-ranging study from the Hoosier Oncology Group. J Clin Oncol 2007;25(18 suppl):7698.
68. Hanna N, Lilenbaum R, Ansari R et al. Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. J Clin Oncol 2006;24:5253-5258.
69. Hanauske A, Weigang Koehler K, Yilmaz E et al. Pharmacokinetic interaction and safety of enzastaurin and pemetrexed in patients with advanced or metastatic cancer. J Clin Oncol 2006;24(18 suppl):2047.
70. ClinicalTrials.gov. A randomized, open-label phase II study of pemetrexed (Alimta) plus carboplatin with or without enzastaurin hydrochloride, or docetaxel plus carboplatin as first line treatment in patients with advanced stage non-small cell lung cancer (NSCLC). Available at http://clinicaltrials. gov/show/NCT00308750. Accessed August 3, 2007.
71. Bennouna J, Breton JL, Tourani JM et al. Vinflunine - an active chemotherapy for treatment of advanced non-small-cell lung cancer previously treated with a platinum-based regimen: Results of a phase II study. Br J Cancer 2006;94:1383-1388.
72. Krzakowski M, Douillard J, Ramlau R et al. Phase III study of vinflunine versus docetaxel in patients with advanced non-small cell lung cancer (NSCLC) previously treated with a platinum-containing regimen. J Clin Oncol 2007;25(18 suppl):7511.
73. ClinicalTrials.gov. A two arm phase I dose escalation trial of vinflunine with erlotinib or pemetrexed in refractory solid tumors. Available at http://www.clinicaltrials.gov/ct/show/NCT00320073. Accessed August 3, 2007.
74. ClinicalTrials.gov. A phase II single arm trial of single-agent vinflunine as second-line treatment of advanced non-small cell lung cancer. Available at http://www.clinicaltrials.gov/ct/show/NCT00251446. Accessed August 3, 2007.
75. ClinicalTrials.gov. LCCC 0503: Phase II study of vinflunine and cetuximab in the second line treatment of stage IIIB/IV non-small cell lung cancer. Available at http://www.clinicaltrials.gov/ct/show/NCT00330031. Accessed August 3, 2007.
76. Norman P. Pemetrexed disodium (Eli Lilly). Curr Opin Investig Drugs 2001;2:1611-1622.
77. Gibbs DD, Theti DS, Wood N et al. BGC 945, a novel tumor-selective thymidylate synthase inhibitortargeted to alpha-folate receptor-overexpressing tumors. Cancer Res 2005;65:11721-11728.